您的当前位置:首页 > 行业数据 > 国内抗抑郁GABA-A受体正向变构调节剂研发格局(截至11M24)
图片属性
图片格式:PNG 图片大小:97KB 图片尺寸:1819*401
同报告图片
 / 4
国内抗抑郁GABA-A受体正向变构调节剂研发格局(截至11M24)_第1页
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
国内抗抑郁GABA-A受体正向变构调节剂研发格局(截至11M24)_第2页
国内抗抑郁GABA-A受体正向变构调节剂研发格局(截至11M24)_第3页
国内抗抑郁GABA-A受体正向变构调节剂研发格局(截至11M24)_第4页
5qC55o2u5Zu+54mH5Lit55qE5pWw5o2u77yM5Lul5LiL5piv6KGo5qC877yaCgp8IOeWvueXheexu+WIqyAgICAgICAgICAgfCDmr5TkvosgKCUpIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18Cnwg5YW25LuW55a+55eFICAgICAgICAgICB8IDgxICAgICAgIHwKfCDogr/nmKQgICAgICAgICAgICAgICB8IDkgICAgICAgIHwKfCDkuK3mnqLnpZ7nu4/ns7vnu5/nlr7nl4UgICB8IDEwICAgICAgIHwKCui1hOaWmeadpea6kO+8mkdCRO+8jOWNjuazsOeglOeptg==
国内抗抑郁GABA-A受体正向变构调节剂研发格局(截至11M24)_第5页
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
所属报告: 翰森制药-港股公司研究报告-创新蕴豪情龙头迎初昕-241229(111页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠